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ORIGINAL RESEARCH
Intestinal Epithelial-Speciﬁc mTORC1 Activation Enhances
Intestinal Adaptation After Small Bowel Resection
Lauren Barron, Raphael C. Sun, Bola Aladegbami, Christopher R. Erwin, Brad W. Warner, and
Jun Guo
Division of Pediatric Surgery, St. Louis Children’s Hospital, Department of Surgery, Washington University School of Medicine,
St. Louis, Missouri

SUMMARY
Activation of intestinal epithelial cell–speciﬁc mammalian
target of rapamycin complex 1 via ablating tuberous sclerosis complex 1 enhances intestinal adaptation. Surprisingly,
intestinal adaptation is not inhibited by inactivating
mammalian target of rapamycin complex 1 activity in the
intestinal epithelial cells, but rather by systemic inactivation
via rapamycin.

BACKGROUND & AIMS: Intestinal adaptation is a compensatory response to the massive loss of small intestine after surgical resection. We investigated the role of intestinal epithelial
cell–speciﬁc mammalian target of rapamycin complex 1
(i-mTORC1) in intestinal adaptation after massive small bowel
resection (SBR).
METHODS: We performed 50% proximal SBR on mice to study
adaptation. To manipulate i-mTORC1 activity, Villin-CreER
transgenic mice were crossed with tuberous sclerosis complex
(TSC)1ﬂox/ﬂox or Raptorﬂox/ﬂox mice to inducibly activate or
inactivate i-mTORC1 activity with tamoxifen. Western blot was
used to conﬁrm the activity of mTORC1. Crypt depth and villus
height were measured to score adaptation. Immunohistochemistry was used to investigate differentiation and rates of
crypt proliferation.

RESULTS: After SBR, mice treated with systemic rapamycin
showed diminished structural adaptation, blunted crypt cell
proliferation, and signiﬁcant body weight loss. Activating
i-mTORC1 via TSC1 deletion induced larger hyperproliferative crypts and disorganized Paneth cells without a
signiﬁcant change in villus height. After SBR, ablating TSC1 in
intestinal epithelium induced a robust villus growth with
much stronger crypt cell proliferation, but similar body
weight recovery. Acute inactivation of i-mTORC1 through
deletion of Raptor did not change crypt cell proliferation
or mucosa structure, but signiﬁcantly reduced lysozyme/
matrix metalloproteinase-7–positive Paneth cell and goblet
cell numbers, with increased enteroendocrine cells.
Surprisingly, ablation of intestinal epithelial cell–speciﬁc
Raptor after SBR did not affect adaptation or crypt proliferation, but dramatically reduced body weight recovery after
surgery.
CONCLUSIONS: Systemic, but not intestinal-speciﬁc, mTORC1
is important for normal adaptation responses to SBR. Although
not required, forced enterocyte mTORC1 signaling after resection causes an enhanced adaptive response. (Cell Mol Gastroenterol Hepatol 2017;3:231–244; http://dx.doi.org/10.1016/
j.jcmgh.2016.10.006)
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ntestinal adaptation after massive small bowel resection (SBR) is a well-established process in which the
remnant bowel compensates for what has been lost.1,2
Adaptation is manifested as enhanced crypt cell proliferation, deeper crypts, and taller villi, resulting in a greater
mucosal surface area. How the remnant small intestine
senses the postresection environmental cues to adapt remains unclear.
Mammalian target of rapamycin (mTOR) is a serine/
threonine kinase that forms 2 functionally and structurally
distinct complexes: mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2).3,4 mTORC1 is a well-known mediator of cell proliferation and cell growth that partners with
regulatory-associated protein of mTOR (Raptor), mammalian lethal with Sec 13 protein 8/G-protein b-protein
subunit like, Akt/Protein Kinase B (PKB) substrate 40
kilodaltons, and DEP-domain-containing mTOR interacting
protein.5,6 Raptor is required for mTORC1 signaling.
mTORC1 activity is regulated by a variety of factors such as
nutrients, growth factors, cellular stress, and energy status.7 In response to growth factor stimulation, the phosphatidylinositol 3 kinase pathway is activated, which will
inactivate tuberous sclerosis complex (TSC)1/2 via phosphorylation.8 TSC1/2 functions to suppress mTORC1 activity by inhibiting the conversion of Rheb–guanosine
diphosphate to Rheb–guanosine triphosphate.4 Knockout
of TSC1/2 therefore results in enhanced mTORC1
signaling. mTORC1 activation leads to phosphorylation of
multiple downstream substrates such as ribosomal protein
S6 kinase (S6K), translation initiation factor 4E binding
proteins, unc-51 like autophagy activating kinase 1/2
(ULK1/2), and autophagy-related gene 13 (ATG13), which
activate anabolic processes such as protein synthesis, lipid
synthesis, and ribosomal biogenesis, while simultaneously
inhibiting autophagy.4,5,7
Rapamycin is the canonical inhibitor of mTORC1 and has
been used extensively for studying mTORC1 function in
various tissues. In the intestine, systemic administration of
rapamycin has been shown to reduce intestinal surface area
in rabbits,9 disrupt intestine regeneration in rats,10 cause
diarrhea in human beings,11 and inhibit intestinal regeneration in acute inﬂammatory bowel disease.12 Repression of
mTORC1 in Paneth cells provides a niche for enhancing
intestinal stem cell proliferation while keeping rates of
proliferation low in transient amplifying cells.13 Similar cellspeciﬁc studies have shown that activating mTORC1 in
enteroendocrine L cells stimulates proglucagon promoter
activity and Glucagon-like peptide-1 (GLP-1) production,14
and that inhibiting mTORC1 activity in adenomatous polyposis coli (Apc)-deﬁcient (Wnt-activated), but not wild-type,
epithelial cells blocks crypt cell proliferation via inhibition
of Eukaryotic Translation Elongation Factor 2 (eEF2) kinase
activity.15 Furthermore, constitutively inactivating mTORC1
in intestinal epithelium affects differentiation and compromises crypt cell regeneration after irradiation injury.16
During intestinal adaptation, the remnant small bowel
mucosa faces an altered environment with different nutrients and growth factors.17,18 Because mTOR can integrate a
multitude of extracellular signals with intracellular cues to
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regulate cell proliferation and cell growth, we hypothesized
that mTOR signaling is a critical factor in adaptation. To test
this hypothesis, we used rapamycin, a systemic mTOR inhibitor, to study the overall systemic role of mTOR signaling
in adaptation. We then applied more sophisticated inducible
and conditional genetic deletion strategies to study the
function of intestinal epithelial cell–speciﬁc mTOR signaling
during adaptation. Speciﬁcally, we determined the effects of
SBR-induced adaptation in mice with enhanced mTORC1
signaling (inducible, intestinal epithelial cell–speciﬁc TSC1/
2 knockouts) as well as in mice with attenuated mTORC1
signaling (inducible, intestinal epithelial cell–speciﬁc Raptor
knockouts).

Materials and Methods
Mice
All protocols and experiments were approved by the
Washington University Animals Studies Committee (protocol 20150285) and followed National Institutes of Health
animal care guidelines. Male C57BL/6 mice, TSC1(ﬂox/ﬂox)
and Raptor(ﬂox/ﬂox) mice, were purchased from the Jackson
Laboratory (Bar Harbor, ME). Villin CreER mice were obtained via a generous donation from Sylvie Robine (Curie
Institute, Paris, France). Intestinal epithelial-speciﬁc TSC1
and Raptor knockout mice were generated by crossing
Villin CreER mice with TSC1(ﬂox/ﬂox) or Raptor(ﬂox/ﬂox),
respectively. Wild-type littermates Villin CreER ();
TSC1(ﬂox/ﬂox) or Villin CreER(-); Raptor(ﬂox/ﬂox) were used as
control mice. Mutant mice were maintained on a C57/BL6
background. Both male and female mice were used for small
bowel resection experiments. Tamoxifen (TAM) (Sigma,
St. Louis, MO) was dissolved in sunﬂower oil at 10 mg/mL and
injected intraperitoneally at 50 mg per gram of body weight for
3 consecutive days to induce deletion of gene expression. Mice
were kept in the animal holding area with a 12-hour light-dark
cycle and given rodent chow ad libitum after weaning.

Small Bowel Resection and Harvest
The 50% proximal SBR procedure has been described
previously.19 The intestinal resections were performed by
transecting the bowel 1- to 2-cm distal from the ligament of
Treitz and at 12-cm proximal to the ileocecal junction, followed by removal of the intervening segment. Intestinal
continuity was re-established by an end-to-end primary
anastomosis using interrupted 9-0 monoﬁlament sutures.
Abbreviations used in this paper: EGF, epidermal growth factor; IHC,
immunohistochemistry; i-TSC-/-, intestinal epithelial cell–speciﬁc
tuberous sclerosis complex 1 null mice; MMP, matrix metalloproteinase;
mTOR, mammalian target of rapamycin; mTORC, mammalian target of
rapamycin complex; PCR, polymerase chain reaction; p-HH3, phosphorylated histone H3; SBR, small bowel resection; S6K, S6 kinase; TAM,
tamoxifen; TSC, tuberous sclerosis complex; WT, wild type.
Most current article
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Mice were provided free access to water for the ﬁrst 24
hours after surgery. Mice then were fed with a standard
liquid diet (PMI Micro-Stabilized Rodent Liquid Diet LD 101;
TestDiet, Richmond, IN) until death.
At the time of death, a midline laparotomy was performed
and the entire small intestine was ﬂushed with ice-cold
phosphate-buffered saline containing protease inhibitors
(0.2 nmol/L phenylmethylsulfonyl ﬂuoride, 5 mg/mL aprotinin, 1 mmol/L benzamidine, 1 mmol/L sodium orthovanadate,
and 2 mmol/L cantharidin). A 2-cm segment of bowel distal to
the anastomosis was ﬁxed in 10% neutral-buffered formalin
for histology. The remainder of the distal segment was used to
isolate crypt and villus.20 Protein extracted from isolated
crypt or villus was used for Western blot assay, and RNA was
used for real-time polymerase chain reaction (PCR) assays.

Histology
Intestinal tissue was parafﬁn-embedded and cut into
5-mm–thick longitudinal sections followed by H&E staining.
Villus height and crypt depth were measured with a videoassisted computer program (NIS elements AR 4; Nikon,
Melville, NY). Crypt depth was measured as the length between the bottom of the crypts and the crypt-villus junction,
and villus height was determined by the length between the
crypt–villi junction and the top of the villus. At least 20
well-oriented crypts and villi were counted per slide. Crypts
were counted only if the crypt–villus junctions on both
sides of the crypt were intact and if Paneth cells were
present at the base of the crypt. Villi were counted only if
the central lymphatic channel extended from the villus base
to the tip and if the mucosal surface was in continuity with
an intact crypt.

Intestinal Epithelial Cell Proliferation and
Differentiation Analysis
Formalin-ﬁxed tissue sections were embedded in
parafﬁn, sectioned, and deparafﬁnized. Alkaline phosphatase activity was detected via immunoﬂuorescence using a
Vector Red Alkaline Phosphatase Substrate kit (Vector
Laboratories, Burlingame, CA). Secretory cell differentiation
and crypt cell mitosis was detected via immunohistochemistry (IHC). Brieﬂy, the deparafﬁnized slides were blocked
with 3% hydrogen peroxide in methanol. Antigen retrieval
was performed using Diva Decloaking solution (Biocare
Medical, Concord, CA) (120 C for 2 minutes using a highpressure cooker). Slides were blocked with avidin-pink
and biotin-blue (Biocare Medical), treated with a speciﬁc
antibody in DaVinci Green (Biocare Medical), incubated
overnight at 4 C, and visualized with biotinylated goat antirabbit IgG (Jackson ImmunoResearch, Inc, West Grove, PA),
followed by streptavidin–horseradish peroxidase (Jackson
ImmunoResearch Laboratories, Inc, West Grove, PA), diaminobenzidine (Sigma-Aldrich, St. Louis, MO), and hematoxylin counterstaining. The antibodies used in this study
were anti–p-histone H3 antibody (9701, 1:400; Cell
Signaling Technology, Danvers, MA) for cell proliferation;
mucin-2 (15334, 1:1000; Santa Cruz, Dallas, TX) for goblet
cell differentiation; chromogranin A (20085, 1:800;
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ImmunoStar, Hudson, WI) for enteroendocrine cell differentiation; matrix metalloproteinase (MMP)-7 (3801, 1:100;
Cell Signaling Technology, Danvers, MA); and lysozyme (RP
028-05, 1:100; Diagnostic Biosystems, Pleasanton, CA) for
Paneth cell differentiation.

Western Blot
Isolated crypt and villus samples were lysed with sodium dodecyl sulfate sample buffer (50 mmol/L Tris-HCL,
pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, and 5%
mercaptoethanol). The lysate then was heated for 5 minutes
at 100 C, and the protein concentration was determined
using the RC-DC kit (Bio-Rad, Hercules, CA). Proteins were
loaded in equal amounts for Western blot. Antibodies used
in this study were as follows: TSC1 (#6935), TSC2
(#4308), Raptor (#2280), pS6K (#9234), S6K (#2708), pS6
(S235/236; #4858), pS6 (S240/244; #5364), S6 (#2217),
glyceraldehyde-3-phosphate dehydrogenase (#5174), and
MMP-7 (#3801) (all from Cell Signaling Technology). The
proteins were detected using the Bio-Rad ChemiDoc XRSþ
system with image Lab software (Bio-Rad).

Real-Time Quantitative PCR
Isolated crypts and villi were homogenized in lysis buffer
and RNA was extracted according to the manufacturer’s
protocol (RNAqueous kit; Ambion, Austin TX). The total RNA
concentration was determined using a NanoDrop Spectrophotometer (ND-1000; NanoDrop Technologies, Wilmington, DE). TSC1, TSC2, MMP-7, and lysozyme primers were
obtained from Life Technologies (Carlsbad, CA). b-actin was
used as the endogenous control (Applied Biosystems, Foster
City, CA). The Applied Biosystems 7500 Fast Real-Time PCR
system was used to obtain relative RNA expression. All
reverse-transcription PCR results are normalized to the
b-actin endogenous control.

Statistical Analysis
All values are reported as means ± SD of the mean.
Statistical analysis was performed using the Student t test to
compare the 2 experimental groups. A P value less than .05
was considered signiﬁcant.

Results
Resection-Induced Intestinal Adaptation Is
Blunted by Rapamycin
To determine whether mTORC1 is involved in intestinal
adaptation after resection, we ﬁrst performed 50% proximal
SBR on male C57BL/6 mice followed by systemic inhibition
of mTORC1 via rapamycin. Small bowel resection is a major
abdominal surgery with a signiﬁcant physiological impact
on the mice in the ﬁrst 48 hours after surgery. In addition,
we see a signiﬁcant decrease in oral intake during this
period despite the rapid regeneration process occurring at
the molecular level.19 Rapamycin injections have a much
smaller, but similar, effect on oral intake and frailty in the
mice. When these 2 procedures are compounded, the postsurgery survival rate decreases sharply. To accommodate,
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Figure 1. Intestinal adaptation, crypt cell proliferation, and postsurgical
weight gain are inhibited
by rapamycin.
Eightweek-old C57BL/6 male
mice were subjected to
50% proximal SBR and
treated with either vehicle
or rapamycin for 7 days. (A)
Representative H&E staining of small intestine 7
days after SBR (n ¼ 7 for
vehicle and n ¼ 8 for
rapamycin). Scale bars:
100 mm. (B) Representative
IHC staining of p-S6 (S235/
236) as a surrogate of
mTORC1 activity (n ¼ 7 per
group). Scale bars: 100
mm. (C) Representative IHC
staining of p-HH3 as a
mitosis marker (n ¼ 7 for
vehicle and n ¼ 8 for
rapamycin). Scale bars: 50
mm. (D) Crypt depth and
villus height measurement
in SBR mice after rapamycin treatment. (E) Average
number of p-HH3–positive
cells per crypt. (F) Representative Western blot
analysis of S6 phosphorylation in isolated small intestine epithelium from
vehicle or
rapamycintreated mice (n ¼ 7 per
group). Lamin B1 was used
as loading control. (G)
Average mice body weight
at the time of harvesting.
Means ± SD are shown.
Student t test (*P < .05).

we allowed the resected mice 48 hours to recover from
surgery before randomization. Mice received a daily 200-mL
intraperitoneal injection of either vehicle (5% Tween-80,
5% polyethylene glycol 400 (PEG-400) in phosphate-

buffered saline) or rapamycin (dissolved in vehicle) for 1
week at a dose of 4 mg/kg. Intestinal histology was obtained
to score structural adaptation. At the same time, crypts, villi,
and the adjacent mesenchyme were separated for detecting
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Figure 2. Small intestine morphology and body weight are not affected by rapamycin treatment in unoperated mice.
Eight-week-old C57BL/6 male mice were subjected to either vehicle (n ¼ 5) or rapamycin (n ¼ 4) treatment for 7 days. (A) Crypt
depth and villus height measurement after vehicle or rapamycin treatment. (B) Average number of p-HH3–positive cells per
crypt. (C) Average body weight gain presented as a percentage of pretreatment weight. Means ± SD are shown. Student t test
(P < .05).

mTORC1 activity in response to rapamycin inhibition. One
week of rapamycin treatment resulted in a diminished
adaptive response as shown by signiﬁcantly decreased villus height (Figure 1A and D). Crypt cell proliferation, as
measured by phosphorylated histone H3 (p-HH3, mitosis
marker) IHC staining, also was decreased signiﬁcantly in
rapamycin-treated SBR mice (Figure 1C and E). The successful inhibition of mTORC1 activity across all layers of
small intestine was conﬁrmed by measuring phosphorylation of ribosomal protein S6, which is a common surrogate
of mTORC1 activity.15,21 In crypts, Western blot assay
showed a dramatic decrease in ribosomal protein S6 phosphorylation at both Ser235/236 and Ser240/244, indicating
decreased mTORC1 signaling (Figure 1F). Because S6

phosphorylation is similar at Ser235/236 and Ser240/244,
only Ser235/236 phosphorylation was recorded for subsequent experiments. IHC staining of small intestine with pS6
antibody conﬁrmed a signiﬁcant reduction of pS6 signal in
rapamycin-treated mice (Figure 1B). When body weight was
measured, rapamycin-treated mice weighed signiﬁcantly less
when compared with vehicle-treated mice (Figure 1G). These
data indicate that systemic mTORC1 signaling is important for
crypt cell proliferation and adaptation after SBR.
To determine whether the effects of rapamycin inhibition were speciﬁc for the adapting bowel, we also treated
unoperated C57BL/6 mice with the same dose of rapamycin
for the same time period. Rapamycin treatment of these
mice did not affect intestinal structure, crypt cell

Figure 3. Acute deletion of TSC1 in intestinal epithelium activates mTORC1 signaling and promotes crypt cell proliferation. Villin CreER (); TSC1(ﬂox/ﬂox) (WT) or Villin CreER (þ); TSC1(ﬂox/ﬂox) (i-TSC1-/-) mice were injected intraperitoneally with
tamoxifen for 3 days and small intestine was removed 2 weeks later. (A) Representative Western blot analysis conﬁrms the
deletion of TSC1 and mTORC1 activation (n ¼ 7 per genotype). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as loading control. (B) Crypt depth and villus height measurement of WT or TSC1-deﬁcient mice (i-TSC1-/-). (C) Crypt cell
proliferation was determined by the number of mitotic cells per crypt, measured by IHC staining using anti–p-HH3 antibody.
(D) Representative H&E staining of small intestine 14 days after TAM injection (n ¼ 7 per genotype). Scale bars: 100 mm.
Means ± SD are shown. Student t test (*P < .05).
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proliferation, or weight gain (Figure 2). These ﬁndings
verify that the mTORC1 signaling pathway is involved
speciﬁcally in the resection-induced adaptation process.

mTORC1 Activation in Intestinal Epithelium
Promotes Adaptation After Resection
Although treatment of mice with rapamycin showed that
systemic mTORC1 signaling is critical for intestinal adaptation after massive SBR, our ultimate goal was to enhance
adaptation responses after SBR. Because of the ubiquitous
nature of mTORC1 signaling throughout the body, tissuespeciﬁc contributions to adaptation may require targeted
mTORC1 activation. Because adaptation is believed to be an
event involving stimulated rates of enterocyte proliferation,22 we focused on genetic manipulation of intestinal
epithelial cells. When bred with Rosa26 reporter mouse line,
the Villin CreER line has been shown to target intestinal stem
cells after TAM injection.23 We therefore crossed the Villin
CreER transgenic mouse with the TSC1(ﬂox/ﬂox) mouse line to
generate inducible intestinal epithelial cell–speciﬁc TSC1
null mice (i-TSC1-/-). When mice reached 6–8 weeks of age,
TAM was injected intraperitoneally for 3 consecutive days.
After 2 weeks, the distal ileum was excised and the deletion
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of TSC1 in i-TSC1-/- mice was conﬁrmed by real-time PCR
using isolated epithelial cells (data not shown). Western blot
then was used to verify the efﬁcient deletion of TSC1 protein
(Figure 3A). As expected, in TSC1-deﬁcient epithelial cells,
the well-established mTORC1 kinase target S6K and S6 were
highly phosphorylated. In addition, protein expression of
TSC2, the binding partner of TSC1, was degraded
(Figure 3A). In contrast, TSC1 protein expression in smooth
muscle was not changed in i-TSC1-/- mice (data not shown).
These results conﬁrm that we successfully established an
inducible intestinal epithelial cell–speciﬁc mTORC1 activation system for further characterization of mTORC1
signaling in the gut. When crypt depth and villus height
were measured, a small, yet signiﬁcant, increase (17.6%) in
crypt depth was seen in unoperated i-TSC1 null mice
(Figure 3B and D). The villus height, however, was not
changed (Figure 3B and D). When the parafﬁn-embedded
slides were stained with p-HH3–speciﬁc antibody to measure crypt cell proliferation, we found 34% more mitotically
active crypt cells in i-TSC1 null mice (Figure 3C).
The literature shows several differing approaches to
determine the role of mTORC1 in intestinal epithelial cell
differentiation. However, these studies have yielded many

Figure 4. The effects of TSC1 deletion on intestinal epithelial cell differentiation. Villin CreER (); TSC1(ﬂox/ﬂox) (WT) or Villin
CreER (þ); TSC1(ﬂox/ﬂox) (i-TSC1-/-) mice underwent intraperitoneal injection with tamoxifen for 3 days and small intestine was
removed 2 weeks later. (A) Representative immunoﬂuorescence staining shows alkaline phosphatase in red (n ¼ 6 per
genotype). (B) Representative IHC shows goblet cells in brown using anti–mucin 2 antibody (n ¼ 6 per genotype).
(C) Representative IHC shows enteroendocrine cells in brown using anti–chromogranin A (ChgA) antibody (n ¼ 6 per genotype). (D) Quantiﬁcation of goblet cells based on at least 30 well-orientated villi. (E) Quantiﬁcation of enteroendocrine cells
based on at least 100 crypt/villus axis. Nuclei are stained with either (A) 40 ,6-diamidino-2-phenylindole or (B and C)
hematoxylin. Scale bars: (A and B) 100 mm, and (C) 50 mm. Means ± SD are shown. Student t test (P < .05).
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different results based on the approach used.16,21 Systemic
inhibition of mTOR or Raptor has been shown to diminish
the activity of alkaline phosphatase.16 In this study, we
found no change in alkaline phosphatase activity within villi
between wild-type (WT) and i-TSC1-/- small intestine
(Figure 4A), which indicates normal absorptive cell lineage
differentiation in the absence of TSC1. Secretory cell
differentiation was investigated (Paneth, goblet, and enteroendocrine cells) with IHC staining using lysozyme, mucin2, and chromogranin A, respectively. We found that
mTORC1 activation through TSC1 ablation in epithelial cells
had no effect on differentiation of goblet and enteroendocrine cells (Figure 4B–E). Because Paneth cell turnover time is much longer (3 to w8 weeks) than other cell
lineages,24–26 we investigated the long-term (4 weeks) effects of TSC1 deﬁciency on Paneth cells. Lysozyme-positive
Paneth cells in WT mice showed a typical clustered pattern
on the bottom of the crypt base. However, lysozyme-positive
cells in i-TSC1-/- crypts were less uniform, yet remained
conﬁned to the crypt compartment (Figure 5A). Despite the
aberrant location of lysozyme-positive cells, the mRNA level
of lysozyme was not changed (Figure 5D). Lysozyme is one
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of many antimicrobial peptides within the granules of
Paneth cells.27 To see whether TSC1 affects the overall
Paneth cells, H&E-stained small intestine was examined.
Indeed, the granule-containing Paneth cells often were not
clustered on the bottom of i-TSC1-/- crypts (Figure 5B). To
further delineate the effects of TSC1 deﬁciency on Paneth
cell function, a metalloproteinase (MMP-7) that regulates
intestinal a-defensin activation was measured.27–29 Similar
to lysozyme staining, MMP-7–positive Paneth cells also
clustered on the bottom of WT crypts, but were disorganized in TSC1-deﬁcient crypts (Figure 5C). The expression
level of MMP-7 protein as shown via Western blot assay was
not affected in TSC1-deﬁcient crypts (Figure 5E). These data
indicate that acute activation of mTORC1 in adult mice affects crypt cell proliferation and Paneth cell organization,
whereas goblet, enteroendocrine, and absorptive cell lineage
differentiation remain undisturbed.
Next, we sought to investigate whether the increased
proliferation seen with increased mTORC1 activation would
promote structural adaptation after SBR. This study was
designed to test whether acute enhancement of mTORC1
activity may have therapeutic beneﬁt in the postoperative

Figure 5. The effects of TSC1 deletion on Paneth cell differentiation. Villin CreER (); TSC1(ﬂox/ﬂox) (WT) or Villin CreER (þ);
TSC1(ﬂox/ﬂox) (i-TSC1-/-) mice underwent intraperitoneal injection with tamoxifen for 3 days and small intestine was removed 4
weeks later. (A) Representative IHC shows Paneth cells in brown using antilysozyme antibody (n ¼ 4 per genotype). Scale bars:
100 mm. (B) Representative H&E staining shows Paneth cell granules in pink (n ¼ 4 per genotype). Scale bars: 50 mm.
(C) Representative IHC shows Paneth cells in brown using anti–MMP-7 antibody (n ¼ 4 per genotype). Scale bars: 100 mm.
(D) Reverse-transcription PCR quantiﬁcation of lysozyme mRNA expression in ileal crypt cells. (E) Representative Western blot
analysis of MMP-7 protein in isolated small intestinal crypt cells (n ¼ 4 for WT and 5 for i-TSC1-/-). Means ± SD are shown.
Student t test (P < .05). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Figure 6. Deletion of TSC1 after intestinal resection promotes adaptation and crypt proliferation. Villin CreER ();
TSC1(ﬂox/ﬂox) (WT) or Villin CreER (þ); TSC1(ﬂox/ﬂox) (i-TSC1-/-) mice underwent SBR and intraperitoneal injection with tamoxifen
for 3 days. The small intestine was removed 2 weeks later. (A) Representative H&E staining of small intestine from SBR (n ¼ 8
per genotype). Scale bars: 100 mm. (B) Crypt depth and villus height measurement of remnant ileum after resection. (C) Crypt
cell proliferation was determined by the number of mitotic cells per crypt, measured by IHC staining using anti–p-HH3 antibody. (D) Western blot analysis was performed to conﬁrm TSC1 ablation and mTORC1 activation (n ¼ 8 per genotype).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. (E) Average weight gain is presented as a
percentage of preoperative weight. Means ± SD are shown. Student t test (*P < .05).

phase after massive SBR. Therefore, we performed SBR on
Villin-CreER(-); TSC1(ﬂox/ﬂox) or Villin-CreER(þ); TSC1(ﬂox/ﬂox)
mice ﬁrst. After a 2-day recovery period, we followed up
with TAM injection for 3 consecutive days to activate

mTORC1 as a means of intervention during the adaptation
process. The magnitude of intestinal adaptation was recorded after 2 weeks. WT mice showed a typical adaptation
response although the response of the i-TSC1-/- mice was

Figure 7. mTORC1 activity accounts for TSC1-deﬁciency–promoted adaptation. Villin CreER (þ); TSC1(ﬂox/ﬂox) mice were
injected intraperitoneally with TAM for 3 days and underwent SBR 1 week later. The resected mice were treated with either
vehicle or rapamycin for 2 weeks. (A) Representative H&E staining of small intestine at the time of harvest (n ¼ 5 for vehicle and
n ¼ 4 for rapamycin). Scale bars: 100 mm. (B) Crypt depth and villus height measurement of remnant ileum after resection.
(C) Crypt cell proliferation was determined by the number of mitotic cells per crypt, measured by IHC staining using p-HH3
antibody. (D) Western blot analysis was performed to conﬁrm rapamycin inhibition of mTORC1 activity (n ¼ 5 for vehicle and
n ¼ 4 for rapamycin). Means ± SD are shown. Student t test (*P < .05).
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Figure 8. Acute deletion of Raptor expression in intestinal epithelial cells does not affect small intestinal structure. Villin
CreER (); Raptor(ﬂox/ﬂox) (WT) or Villin CreER (þ); Raptor(ﬂox/ﬂox) (i-Raptor-/-) mice were injected intraperitoneally with tamoxifen
for 3 days and small intestine was removed 2 weeks later. (A) Western blot analysis conﬁrms Raptor deﬁciency and mTORC1
pathway inhibition (n ¼ 7 per genotype). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control.
(B) Crypt depth and villus height measurements of WT and Raptor-deﬁcient mice. (C) Crypt cell proliferation was determined by
the number of mitotic cells per crypt, measured by IHC using anti–p-HH3 antibody. (D) Representative H&E staining of small
intestine at the time of harvest (n ¼ 7 per genotype). Scale bars: 100 mm. Means ± SD are shown. Student t test (P < .05).

much stronger (w20% greater villus growth) (Figure 6A
and B). Crypt proliferation in i-TSC1-/- mice, as shown by pHH3 IHC staining, was 44% more than in the WT mice
(Figure 6C). The activation of mTORC1 signaling in resected
mice was conﬁrmed by decreased TSC2 expression and
increased phosphorylation of pS6 and S6K in epithelial cells
(Figure 6D). Despite the increased structural intestinal
adaptation, the i-TSC1-/- mice did not gain more weight
than WT mice at 2 weeks after resection (Figure 6E).
We wanted to conﬁrm that the proliferative and
adaptive responses seen after SBR were owing to mTORC1
activation secondary to TSC1 inhibition rather than an
alternate function of TSC1 protein. To test this, we injected
mice with 3 doses of TAM to delete TSC1 ﬁrst, waited for a
week, and then performed SBR procedures on i-TSC1-/mice. The modiﬁed research design was to focus on the
role of TSC1 and simultaneously avoid the stress of
injecting both TAM and rapamycin in postsurgical mice.
After a 2-day recovery, the resected mice were randomized and treated with either vehicle or rapamycin (to
inhibit mTORC1) for 2 weeks. We found that adaptation as
well as resection-induced crypt cell proliferation was
diminished by rapamycin treatment in i-TSC1-/- mice
(Figure 7A–C). The inhibition of mTORC1 in the
rapamycin-treated mice was conﬁrmed by Western blot
(Figure 7D). These data clearly verify that the enhanced
proliferation and adaptation seen in TSC1-null mice after
SBR is owing to the activated mTORC1 signaling pathway
within intestinal epithelial cells. It also suggests that
resection-induced crypt cell proliferation could be

modulated by enhancing intestinal epithelial cell mTORC1
activity.

mTORC1 Inactivation in Intestinal Epithelium
Does Not Affect Adaptation
We have established that intestinal epithelial-speciﬁc
activation of mTORC1 is capable of enhancing adaptation
after SBR. However, it was not clear after the systemic
rapamycin inhibition study whether mTORC1 signaling in
intestinal epithelium is necessary for normal adaptation to
occur. To investigate this, we bred Villin CreER mice with
Raptor(ﬂox/ﬂox) mice to delete Raptor protein as a means of
inactivating mTORC1 speciﬁcally in epithelial cells. The
same experimental design in TSC1 null mice was adopted
for this study. We ﬁrst conﬁrmed the deletion of Raptor
protein in epithelial cells (Figure 8A). The downstream
protein kinase S6K was phosphorylated at baseline but was
undetectable when Raptor was deleted. In addition, pS6
phosphorylation was greatly reduced in the absence of
Raptor. Despite the lack of mTORC1 signaling in the
i-Raptor-/- mice, the structure of the small intestine did not
change (Figure 8B and D). Rates of crypt cell proliferation
were the same as in WT mice (Figure 8C), which is consistent with previously published data.15 In addition, alkaline
phosphatase activity was not changed, verifying that
enterocyte maturation was not altered (Figure 9A). When
secretory cell lineage differentiation was analyzed via IHC
staining using cell differentiation speciﬁc markers, we found
that goblet cells were decreased, whereas enteroendocrine
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Figure 9. Acute deletion of Raptor expression in intestinal epithelium affects differentiation. Villin CreER (); Raptor(ﬂox/ﬂox)
(WT) or Villin CreER (þ); Raptor(ﬂox/ﬂox) (i-Raptor-/-) mice underwent intraperitoneal injection with tamoxifen for 3 days and small
intestine was removed after 2 weeks. (A) Representative immunoﬂuorescence staining shows alkaline phosphatase in red (n ¼
7 per genotype). (B) Representative IHC shows goblet cells in brown using anti–mucin 2 antibody (n ¼ 7 per genotype).
(C) Representative IHC shows enteroendocrine cells in brown using anti–chromogranin A (ChgA) antibody (n ¼ 7 per genotype). (D) Quantiﬁcation of goblet cells based on at least 30 well-orientated villi. (E) Quantiﬁcation of enteroendocrine cells
based on at least 100 crypt/villus axis. Nuclei are stained with either (A) 40 ,6-diamidino-2-phenylindole or (B and C)
hematoxylin. Scale bars: (A and B) 100 mm, and (C) 50 mm. Means ± SD are shown. Student t test (*P < .05).

cells were increased in the absence of intestinal epithelialspeciﬁc Raptor (Figure 9B–E). Lysozyme-positive Paneth
cells were greatly reduced after 4 weeks (Figure 10A). The
granule-containing Paneth cells also were diminished in
Raptor-deﬁcient crypts in H&E-stained tissue (Figure 10B).
Moreover, the expression of MMP-7 also was reduced
dramatically in Raptor-deﬁcient crypts (Figure 10C and F).
Surprisingly, neither lysozyme nor MMP-7 mRNA expression levels were affected (Figure 10D and E), suggesting that
Raptor protein may have a role in the translational regulation of lysozyme and MMP-7 expression during Paneth cell
maturation.
Sampson et al16 previously showed that mTORC1 activity
is required for crypt regeneration after irradiation-induced
intestinal injury. We therefore sought to determine
whether mTORC1 activity is necessary for resectionstimulated crypt cell proliferation. A similar strategy was
used in which SBR was performed on Villin CreER(-); Raptor(ﬂox/ﬂox) mice and Villin CreER(þ); Raptor(ﬂox/ﬂox) mice.
Two days after surgery TAM was given via intraperitoneal
injection for 3 consecutive days to inactivate the mTORC1
pathway in the intestinal epithelium. Adaptation was
analyzed 2 weeks later. Remarkably, crypt depth and villus
height in i-Raptor-/- mice was the same as in WT mice

(Figure 11A and B). Crypt cell proliferation, as measured by
p-HH3 IHC, also was not changed (Figure 11C). Blocked
mTORC1 signaling in Raptor-deﬁcient mice was conﬁrmed
(Figure 11D). Despite the normal structural adaptation, the
Raptor-deﬁcient mice had signiﬁcantly more weight loss
after surgery than the WT mice (Figure 11E).
In summary, our results show that mTORC1 activity in
intestinal epithelial cells is not required for crypt proliferation and has different effects on enterocyte differentiation.
Furthermore, resection-induced crypt proliferation and intestinal adaptation requires systemic, but not intestinal
epithelial-speciﬁc, mTORC1 activity. However, stimulation of
mTORC1 in intestinal epithelium increases crypt cell proliferation, which further enhances adaptation after SBR
(Figure 12). The long-term functional signiﬁcance of
manipulating mTORC1 signaling in intestinal epithelial cells
after small bowel resection remains unclear and will require
further studies.

Discussion
The mTOR signaling pathway has been studied extensively because it is a master regulator of cell proliferation,
growth, and metabolism.3,4,6,30 Historically, the majority of
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Figure 10. The effects of Raptor deletion on Paneth cell differentiation. Villin CreER (); Raptor(ﬂox/ﬂox) (WT) or Villin CreER
(þ); Raptor(ﬂox/ﬂox) (i-Raptor-/-) mice underwent intraperitoneal injection with tamoxifen for 3 days, small intestine was removed
4 weeks later. (A) Representative IHC shows Paneth cells in brown using antilysozyme antibody (n ¼ 4 per genotype). Scale
bars: 100 mm. (B) Representative H&E staining shows Paneth cell granules in pink (n ¼ 4 per genotype). Scale bars: 50 mm.
(C) Representative IHC shows Paneth cells in brown using anti–MMP-7 antibody (n ¼ 4 per genotype). Scale bars: 100 mm.
(D) Reverse-transcription PCR quantiﬁcation of lysozyme mRNA expression in ileal crypt cells. (E) Reverse-transcription PCR
quantiﬁcation of MMP-7 mRNA expression in ileal crypt cells. (F) Representative Western blot analysis of MMP-7 protein in
isolated small intestine epithelium (n ¼ 4 per genotype). Means ± SD are shown. Student t test (P < .05). GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.

these studies were based in cell culture. However, more
recently, studies have emerged with tissue/organ-speciﬁc
research that has shown varied physiological functions of
mTOR in adult tissues and during development.12,13,15,16,31
In intestinal tissue, several groups have used various strategies to manipulate mTOR signaling and have yielded dissimilar results. For example, using a similar strategy to
constitutively delete mTOR protein speciﬁcally in intestinal
epithelial cells,11,16 one group clearly showed a dilated small
bowel with a reduced body weight.11 On the other hand,
another group found that the mTOR-deﬁcient mice have a
shorter small bowel but a similar body weight.16
There is also some controversy regarding the role of
mTOR signaling in intestinal cell differentiation. One report
found that intestinal epithelial-speciﬁc mTOR signaling is
required for proper lysozyme transcription in Paneth
cells.16 However, other studies found that mTOR activation
via a constitutive systemic TSC2 mutation also impaired
lysozyme expression in Paneth cells.21 By using an inducible
Cre system to manipulate mTOR signaling in adult intestinal
epithelial cells, we found that Paneth cell differentiation was

indeed regulated by mTORC1 signaling in intestinal
epithelial cells, but via a different mechanism. mTORC1
inactivation does not inhibit lysozyme or MMP-7 transcription, rather, it appears to regulate lysozyme or MMP-7
translation. Activating mTORC1 in intestinal epithelium, on
the other hand, appears to affect Paneth cell clustering on
the base of crypts. Maturation of enterocytes also has been
found to be disrupted in mTOR or Raptor-deﬁcient cells
based on alkaline phosphatase activity.16 In our acute
ablation model, we did not see any alteration in the
expression of alkaline phosphatase in Raptor- or TSCdeﬁcient mice. These seemingly conﬂicting studies may be
explained by the different methods used in each study to
manipulate mTOR signaling and may represent different
aspects of regulation during enterocyte differentiation. In
the TSC2 mutant model,21 mTORC1 activation caused by
loss of the functional TSC2 was not conﬁned to the intestine.
The mesenchyme, as well as other tissues, also would show
mTORC1 activity, confounding the autonomous role of
mTOR in intestinal epithelial cells. In the enterocyte mTORdeﬁcient model,16 villin Cre was activated from embryonic
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Figure 11. Deletion of Raptor expression in intestinal epithelium after small bowel resection does not affect adaptation.
Villin CreER (); Raptor(ﬂox/ﬂox) (WT) or Villin CreER (þ); Raptor(ﬂox/ﬂox) (i-Raptor-/-) mice underwent 50% SBR, followed by
intraperitoneal injection with tamoxifen for 3 days and small intestine was removed 2 weeks later. (A) Representative H&E
staining of small intestine at the time of harvest (n ¼ 5 for WT and 8 for i-Raptor-/-). Scale bars: 100 mm. (B) Crypt depth and
villus height in remnant ileum after resection. (C) Crypt cell proliferation was determined by the number of mitotic cells per
crypt, measured by IHC staining using anti–p-HH3 antibody. (D) Representative Western blot analysis was performed to
conﬁrm Raptor ablation and mTORC1 inactivation (n ¼ 5 for WT and n ¼ 8 for i-Raptor-/-). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as loading control. (E) Average weight gain presented as the percentage of preoperative weight. Means ± SD are shown. Student t test (*P < .05).

day 12.5, which suggests that mTORC1 activity may be
required during the development of Paneth cells as well as
absorptive enterocyte differentiation. The multitude of
differing results illustrates the complexity of the mTORC1
signaling pathway in regulating development and maintenance of the small intestine.
In this study, we investigated the role of mTORC1 during
normal intestinal homeostasis as well as during the adaptive
response after massive SBR. Although inactivating mTORC1
signaling in intestinal epithelium has no effect on intestinal
structure or the adaptive response after resection, we found
that stimulating mTORC1 resulted in enhanced crypt proliferation in adult mice. In addition, we showed that after
massive SBR, adaptation and crypt proliferation were
enhanced further when mTORC1 was activated in remnant
small bowel. The notion that the function of mTORC1 differs
during homeostasis and regeneration after injury has been
established.15,16,32 Constitutively ablating mTOR or Raptor

Figure 12. Summary of mTORC1
small-bowel adaptation after resection.

regulation

of

in intestinal epithelial cells has little effect on crypt cell
proliferation and Wnt activity in the normal intestine.
However, when mTORC1 signaling was absent, crypt
regeneration after irradiation injury was compromised.16 In
Apcmin/+ mice, mTORC1 activity is required for Wntmediated intestinal polyp formation, likely via regulating
the translational elongation rate.15,32 Our results support
the notion that mTORC1 regulates intestinal homeostasis
and recovery after injury by different mechanisms. However, they also provide a clear distinction between the
mechanism behind adaptation and that of Wnt-mediated
crypt growth. Raptor deﬁciency alone is not sufﬁcient to
alter small intestine proliferation or adaptation after
massive SBR, which indicates pathways other than the Wnt
pathway may be crucial for regulating adaptation.
Inhibiting mTORC1 via rapamycin systemically, but not
by Raptor deﬁciency in intestinal epithelial cells, blunted
crypt cell proliferation and adaptation after SBR. It is
possible that rapamycin may have other unknown targets
aside from mTORC1 that regulate crypt cell proliferation.
Alternatively, it must be considered that intestinal epithelial
cells possess a redundant system to compensate for the loss
of mTORC1 signaling to maintain proliferation and growth.
However, this theory contradicts the ﬁndings that Raptordeﬁcient crypts do not grow into organoid outside of the
intestine niche in vitro.15 The more plausible mechanism to
consider is that mTOR signals originating from the mesenchyme or the surrounding tissues play a critical role in this
process, given that mTOR functions in a non–cell-autonomous manner.30 The critical role of mesenchyme
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subepithelial ﬁbroblasts in maintaining intestinal niche
function was established clearly in a recent report.33 It appears that non–cell-autonomous mTORC1 signaling is
crucial for the small bowel adaptive response after
resection.
It is well known that nutrients and growth factors can
enhance adaptation after resection.18,22,34 We previously
showed that a high-protein diet improves postoperative
weight gain in resected mice,35 an effect possibly owing to
the higher glutamine levels in the high-protein diet. Glutamine has been shown to stimulate mTOR signaling and
promote crypt expansion.36 Our laboratory previously has
shown that epidermal growth factor (EGF) treatment will
increase the adaptive response after resection.37 Because
EGF stimulation activates phosphatidylinositol 3 kinase, it
may destabilize the TSC1/TSC2 complex, causing increased
mTORC1 activation and enhanced adaptation. Interestingly,
we recently discovered that the intestinal epitheliumspeciﬁc EGF receptor is not necessary for adaptation.38
These EGF and mTORC1 studies provide a similar pattern
for how adaptation might be regulated. The crypt niche is
crucial to provide cues for adaptation to occur; when the
cues are present, adaptation can be manipulated in an
enterocyte-dependent manner.
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